Phase I/II Clinical Trials of SHR-8203 Injection in Participants With Advanced Solid Tumors

Inclusion Criteria: 1. Age between 18 and 75 years old, gender not limited; 2. Be willing to participate and abide by the requirements of the research protocol, and be willing to cooperate with the follow-up. 3. Participants with advanced or metastatic solid tumors confirmed by histological or cytological pathology who have failed standard treatment (disease progression or toxic intolerance) or have no effective standard treatment; 4. Able to provide sufficient fresh or archived tumor tissue specimens for the third-party central laboratory designated by the sponsor. 5. Have at least one measurable lesion as per RECIST v1.1; 6. ECOG PS score: 0-1; 7. Good organ function level. Exclusion Criteria: 1. Imaging studies show that the tumor invades major blood vessels or has an unclear boundary with blood vessels, and researchers determine that there is a risk of massive hemorrhage; 2. Suffering from hypertension and unable to achieve good control through antihypertensive drug treatment; 3. Pleural effusion, pericardial effusion or peritoneal effusion accompanied by clinical symptoms, poorly controlled, or moderate to severe; 4. Major arterial or venous thrombosis events occurred within 6 months before the first administration of medication; 5. Participants who have experienced severe infections within one month prior to the first medication.